Clinical trial
Docetaxel in Treating Patients With Recurrent or Persistent Endometrial…
NCT00085332 · Gynecologic Oncology Group, Other · Completed
Key facts
| NCT number | NCT00085332 |
|---|---|
| Title | Docetaxel in Treating Patients With Recurrent or Persistent Endometrial Carcinoma (Cancer) |
| Official title | A Phase II Evaluation of Weekly Docetaxel (NSC #628503) in the Treatment of Recurrent or Persistent Endometrial Carcinoma |
| Lead sponsor | Gynecologic Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Endometrial Cancer |
| Intervention type | Drug |
| Interventions | docetaxel |
| Start date | Jul 1, 2004 |
| Primary completion | Dec 1, 2005 |
| First posted | Jun 11, 2004 |
| Last update posted | Jan 13, 2014 |
| Countries | Australia, Canada, Japan, Norway, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: